New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 23, 2014
09:13 EDTCYTKCytokinetics should be owned ahead of data, says Roth Capital
Roth Capital recommends that investors own Cytokinetics ahead of data expected to be unveiled on April 29. The firm thinks the data could be "a transformational event" for the company, and reiterates a $25 price target and Buy rating on the shares.
News For CYTK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for CYTK

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use